|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Seth Gordhandas Sunderdas Medical College |
|---|---|
| Information provided by: | Seth Gordhandas Sunderdas Medical College |
| ClinicalTrials.gov Identifier: | NCT00889525 |
Purpose
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.
Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.
| Condition | Intervention | Phase |
|---|---|---|
|
Cushing's Disease Corticotroph Adenoma |
Drug: Cabergoline |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study |
| Official Title: | Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor |
| Study Start Date: | November 2007 |
| Arms | Assigned Interventions |
|---|---|
| Cabergoline: Experimental |
Drug: Cabergoline
Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
|
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| India, Maharashtra | |
| Seth GSMC & KEM hospital | |
| Mumbai, Maharashtra, India, 4000012 | |
| Principal Investigator: | Nalini S Shah, DM | Seth GSMC and KEM hospital, Mumbai |
More Information
| Responsible Party: | Seth Gordhandas Sunderdas Medical College& KEM Hospital ( Dr Nalini S Shah ) |
| Study ID Numbers: | EC/104/2005 |
| Study First Received: | April 27, 2009 |
| Last Updated: | April 28, 2009 |
| ClinicalTrials.gov Identifier: | NCT00889525 History of Changes |
| Health Authority: | India: Drugs Controller General of India |
|
Cabergoline |
|
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Antineoplastic Agents Physiological Effects of Drugs Antiparkinson Agents Central Nervous System Neoplasms Pituitary Neoplasms Dopamine Agonists Brain Diseases Pituitary ACTH Hypersecretion Neoplasms by Site Hyperpituitarism Hypothalamic Neoplasms Therapeutic Uses |
Nervous System Neoplasms Endocrine Gland Neoplasms Hypothalamic Diseases Neoplasms by Histologic Type Pituitary Diseases Nervous System Diseases Central Nervous System Diseases Endocrine System Diseases Supratentorial Neoplasms Pharmacologic Actions ACTH-Secreting Pituitary Adenoma Brain Neoplasms Neoplasms Dopamine Agents Central Nervous System Agents |